Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BGI Sanshengyuan is a health management subsidiary of the BGI Group, focusing on precision nutrition and personalized health interventions. The company leverages BGI's extensive genomic and multi-omic data to provide services such as gut microbiome testing and tailored nutritional supplements. Their business model integrates advanced biotechnology with traditional health practices to address chronic diseases and improve overall wellness. Key offerings include the "Sansheng" series of probiotic products and comprehensive health assessment programs. By utilizing big data and biological insights, BGI Sanshengyuan aims to provide actionable health interventions for metabolic and digestive conditions. The company operates primarily in China, serving as a bridge between BGI's research capabilities and consumer health needs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BGI Sanshengyuan.